The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

Roflumilast foam, 0.3%, proved to be a simplified treatment regimen with high efficacy for patients with scalp and body ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

The trial investigators wanted to see if the drug was an effective psoriasis treatment ... Scalp-Investigator Global Assessment (S-IGA) and Body-IGA (B-IGA) scores. Both are five-point scales ...

may improve treatment outcomes by increasing adherence. Roflumilast foam, 0.3% (Zoryve) used once-daily significantly improved itch and other symptoms of plaque psoriasis of the scalp and body ...

Icotrokinra demonstrated high rates of clearance in scalp and genital psoriasis after 16 weeks of treatment, according to ...

Ringworm is the common name for an infection, called tinea. The name comes from the shape of the rash, a thin red circle with a clear middle. But it has nothing to do with a worm and everything to ...

The IGA is a five-point scale with a severity ... A study of JNJ-2113 for the treatment of participants with plaque psoriasis involving special areas (scalp, genital, and/or palms of the hands ...